064 Temporal trends in prescription rates of recommended treatments in chronic heart failure outpatients: a comparison of three French surveys IMPACT RECO I, II & III

详细信息    查看全文

• 作者：Patrick Assyag¹ ; Pascal De Groote² ; Michel Galinier³ ; Guillaume Jondeau⁴ ; Nacima Demil⁵ ; Richard Isnard⁶ ; Alain Ducardonnet⁷ ; Jean-Franç ; ois Thé ; baut⁸ ; Michel Komajda⁶
• 刊名：Archives of Cardiovascular Diseases Supplements
• 出版年：2010
• 出版时间：January 2010
• 年：2010
• 卷：2
• 期：1
• 页码：22
• 全文大小：91 K

文摘

Background

Recent registries have shown that recommended drugs for the treatment of congestive heart failure (CHF) remain under-prescribed in daily practice.

Aims

To compare prescription rates of CHF drugs in three French surveys Impact Reco I, II and III.

Methods

We included outpatients followed by private cardiologists: 1947 in Impact Reco I (2005), 1974 in Impact Reco II (2005/2006) and 1574 in Impact Reco III (2007), with NYHA class II-IV heart failure and a left ventricular ejection fraction < 40 % , and we compared treatment modalities. Recommended treatments and target doses were defined according to ESC guidelines.

Results

There was an improvement in both the rate of prescription, and in the proportion of patients reaching target dose or 50 % of target dose of ACE I, ARBs and beta blockers (see table).

Conclusion

Prescription			IMPACT I 2005	IMPACT II 2005/2006	IMPACT III 2007
	Global population		1917	1974	1574
ACE I	Number patients with prescription	N ( % )	1361 (71.0)	1349 (68.3)	1099 (70.2)
Target dose	%	48.7	57.3*	52.3?/sup>
50 % Target dose	%	80.4	84.5*	88.4?/sup>,?/sup>
ARBs	Number patients with prescription	N ( % )	395 (20.6)	592 (30.0)*	516 (33.3)?/sup>,?/sup>
Target dose	%	9.1	7.4	20.7?/sup>,?/sup>
50 % Target dose	%	52.9	49.7	68.6?/sup>,?/sup>
Betablockers	Number patients with prescription	N ( % )	1245 (65.2)	1382 (70.0)*	1229 (78.3)?/sup>,?/sup>
Target dose	%	18.4	23.4*	25.7?/sup>
50 % Target dose	%	47.3	53.5*	59.9??/sup>